James R. Kasinger - 29 May 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: General Counsel and Secretary
Issuer ticker: CRSP
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 17:42:26 UTC
Prior SEC filing: 24 Mar 2026
Source filing: View source filing
Reporting owner signature: Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

James R. Kasinger filed Form 4 for CRISPR Therapeutics AG (CRSP) on 02 Jun 2026.

Key facts

This page summarizes James R. Kasinger's Form 4 filing for CRISPR Therapeutics AG (CRSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2026, 17:42.

Change

Previous filing in this sequence was filed on 24 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001708172 Primary reporting owner

KASINGER JAMES R.

Relationship: General Counsel and Secretary
Address: C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: Elizabeth Ryland Waldinger, attorney-in-fact
Signature date: 02 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +17,000
Change %
Price: $0.000000^*
Shares after: 17,000
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 17,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F2

This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028.